D E Shaw Increases Stake In Beazer Homes USA, Inc. (BZH)

David E. Shaw is optimistic about the prospects of Beazer Homes USA, Inc. (NYSE:BZH) and has added to his fund’s position in this stock. As reported in a recent filing with the Securities and Exchange Commission, D E Shaw has increased its holding of the stock from approximately 764,000 to 1.35 million shares, thus amassing 5.1% of the total number of shares outstanding.

David E. Shaw Vertex Pharmaceutical

Beazer Homes USA, Inc. (NYSE:BZH) has attracted the attention of several other hedge fund gurus. Ken Griffin has increased his fund’s holding of this stock by 97% during the first quarter of this year. As reported in its latest 13F filing, Citadel Investment Group holds 1.53 million shares. Charles Clough, the manager of Clough Capital Partners, has also increased his fund’s holding by 63% to 1.23 million shares. Tom Brown and his fund, Second Curve Capital, have also boosted their position by 59%, taking it to approximately 707,900 shares.

Beazer Homes USA, Inc. (NYSE:BZH) engages in the building and sale of homes throughout the United States. So far this year the stock has tumbled 14% to a current price of $20.93 per share, giving the company a market cap of $559 million. For the three months ending March 31, 2014, the company has reported $270 million in revenues, down 6% year-over-year, and a loss of $0.32 per share. Analysts expect Beazer Homes to announce revenues of $362 million and earnings per share of $0.24 for the current quarter.

David E. Shaw is betting big on Liberty Global plc – Class C Ordinary Shares (NASDAQ:LBTYK), having increased his fund’s stake by 501% during the first quarter of 2014. In its latest 13F filing, D E Shaw has reported ownership of 14.6 million shares. His top equity position is Berkshire Hathaway Inc. (NYSE:BRK.B) – 8.73 million shares, up 5% during the same period. Shaw has also added to his fund’s stake in General Electric Company (NYSE:GE), taking it to 22.8 million shares.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!